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Abstract 
Malnutrition is a frequent problem in cancer patients, which leads to prolonged hospitalization, a 
higher degree of treatment-related toxicity, reduced response to cancer treatment, impaired 
quality of life and a worse overall prognosis. The attitude towards this issue varies considerably and 
many malnourished patients receive inadequate nutritional support.  
We reviewed available data present in the literature, together with the guidelines issued by sci-
entific societies and health authorities, on the nutritional management of patients with cancer, in 
order to make suitable and concise practical recommendations for appropriate nutritional support 
in this patient population. Evidence from the literature suggests that nutritional screening should 
be performed using validated tools (the Nutritional Risk Screening 2002 [NRS 2002], the Mal-
nutrition Universal Screening Tool [MUST], the Malnutrition Screening Tool [MST] and the Mini 
Nutritional Assessment [MNA]), both at diagnosis and at regular time points during the course of 
disease according to tumor type, stage and treatment. Patients at nutritional risk should be 
promptly referred for comprehensive nutritional assessment and support to clinical nutrition 
services or medical personnel with documented skills in clinical nutrition, specifically for cancer 
patients. Nutritional intervention should be actively managed and targeted for each patient; it 
should comprise personalized dietary counseling and/or artificial nutrition according to sponta-
neous food intake, tolerance and effectiveness. Nutritional support may be integrated into pallia-
tive care programs. “Alternative hypocaloric anti-cancer diets” (e.g. macrobiotic or vegan diets) 
should not be recommended as they may worsen nutritional status.  
Well-designed clinical trials are needed to further our knowledge of the nutritional support re-
quired in different care settings for cancer patients. 
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Introduction 
Malnutrition is a frequent problem in cancer pa-
tients, whose prevalence and degree mainly depend 
on tumor stage and site (1). Its negative consequences 
are prolonged hospitalization, a higher degree of 
treatment-related toxicity, reduced response to cancer 
treatment, lower activity level, impaired quality of life 
and a worse overall prognosis (2). Even minimal 
weight loss during chemo/radiotherapy (CRT) is as-
sociated with significantly reduced survival (3). 
Nutritional support is a step by step interven-
tion, which should be actively managed and targeted 
for each patient according to nutritional conditions, 
clinical status, planned oncologic treatment and ex-
pected outcome. Its goal is preventing or treating 
malnutrition, in order to allow the successful comple-
tion of oncologic treatments, improve prognosis and 
preserve functional status and quality of life (4, 5).  
Although recommendations on the optimal 
management of nutritional support for patients with 
malignancies have been provided (4, 6, 7), the attitude 
towards this issue varies considerably among oncol-
ogists, sometimes even within one center, and an 
important proportion of malnourished patients is re-
ported not to receive adequate nutritional support (1). 
This could be related to the continuing insufficient 
awareness of nutritional problems among health care 
professionals (8), the lack of structured collaboration 
between oncologists and clinical nutrition specialists 
and the still limited number of clinical trials aimed at 
improving our understanding of the nutritional sup-
port required in different care settings for cancer pa-
tients.  
Another worrying issue, which may hamper the 
appropriate nutritional care of cancer patients, is the 
expanding market of “alternative anti-cancer diets”, 
which are not supported by scientific evidence and 
may lead to insufficient protein-calorie intake.  
The purpose of this paper is to highlight the nu-
tritional issues in cancer patients, thus allowing the 
Italian Association of Medical Oncology (AIOM) and 
the Italian Society of Artificial Nutrition and Metabo-
lism (SINPE) to make suitable and concise practical 
recommendations for appropriate nutritional support 
in this patients’ population. 
We reviewed the available literature – prioritiz-
ing meta-analyses, systematic reviews and random-
ized controlled trials where available – and interna-
tional guidelines on the nutritional management of 
patients with cancer. In addition, experts from the two 
societies, who are listed among the authors, provided 
additional clinical information which helped in clari-
fying some issues. 
Nutritional screening and assessment  
Early recognition of nutritional problems is the 
first key point for appropriate nutritional manage-
ment of cancer patients. Different tools for nutritional 
screening have been validated in the oncologic setting 
and effectively allow the identification of patients at 
nutritional risk, who are likely to benefit from nutri-
tional support. They are: the Nutritional Risk Screen-
ing 2002 (NRS 2002), the Malnutrition Universal 
Screening Tool (MUST), the Malnutrition Screening 
Tool (MST) and the Mini Nutritional Assessment 
(MNA) (9).  
Nutritional screening should be performed using 
a validated tool upon diagnosis and systematically 
repeated at regular time points during the course of 
disease in patients with cancer type, stage or treat-
ment potentially affecting nutritional status.  
Patients at nutritional risk should be promptly 
referred for comprehensive nutritional assessment 
and support to clinical nutrition services or medical 
personnel with documented skills in clinical nutrition, 
specifically for cancer patients. 
Recent studies have highlighted the importance 
of assessing body composition in cancer patients (10). 
Bioelectrical impedance vectorial analysis (BIVA) can 
be performed in different clinical settings and allow 
the suitable assessment of patients in whom calcula-
tion of body composition fails due to altered hydra-
tion (11). In particular, the primary output measure of 
this technique, phase angle, was found to be associ-
ated with functional status (12) and energy intake 
(13), and to be predictive of quality of life and prog-
nosis in cancer patients (12, 14). As nutritional therapy 
is primarily intended to preserve or restore lean body 
mass, the assessment of body composition by BIVA 
should be integrated in the nutritional assessment of 
cancer patients. 
Indications for nutritional support  
Indications for nutritional support in cancer pa-
tients vary throughout the continuum of care, de-
pending on whether patients are undergoing active 
oncologic treatment, are in remission or in a palliative 
stage. This means that regular nutritional monitoring 
is mandatory in all patients with cancer type, stage or 
treatment potentially affecting nutritional status.  
Nutritional interventions should compensate for 
inadequate energy intake with the objective of im-
proving clinical outcomes (4, 6, 7, 15).  
The correct identification of candidates for nu-
tritional support relies on the evaluation of current 
and expected nutritional status and energy intake. 
Accordingly, nutritional support should be provided 
to malnourished patients and those at nutritional risk, 
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in particular when oral energy intake is already in-
sufficient or expected to be inadequate (<60% of es-
timated caloric requirements) for more than 7 days (4, 
6, 7, 15).  
Undernourished cancer patients with planned 
elective surgery should receive at least 7-day 
pre-operative nutritional support to improve 
post-operative outcomes, even if this may delay sur-
gery (16).  
Dietary counseling, including the use of oral 
nutritional supplements (ONS), should be the 
first-step towards achieving satisfactory energy in-
take. In presence of normal gut function and inade-
quate food intake, total or integrative enteral tube 
feeding must be considered. If enteral nutrition (EN) 
is not feasible due to gut dysfunction, symptoms 
which could be worsened by enteral support (i.e. 
nausea, vomiting, diarrhea) or patients’ refusal, par-
enteral nutrition (PN) is required for delivering nutri-
tional support (4, 6, 7, 15).  
Nutritional counseling, complementary 
nutrients and oral nutritional supple-
ments 
Nutritional counseling is the first-line of treat-
ment in malnourished cancer patients or in those at 
nutritional risk, due to its proven efficacy in increas-
ing protein-calorie intake, body weight and improv-
ing body composition (17, 18). In head and neck can-
cer patients undergoing CRT, nutritional counseling 
was found to be associated with lower CRT toxicity 
and symptom-induced morbidity (19), and to have 
beneficial effects on quality of life (20). Individualized 
nutrition intervention was also shown to improve 
survival in colorectal cancer patients (21). 
Therefore, all malnourished or at nutritional risk 
cancer patients who are able to eat should be referred 
to a dietitian with documented skills in cancer patient 
care for appropriate dietary intervention and its 
monitoring. While taking into account individual 
preferences, ethnicity and culture, the optimization of 
oral diet should consider predominantly the issue of 
appropriate protein-calorie content and texture, in 
order to cope with nutritional deficiencies and swal-
lowing difficulties. In addition, any practical sugges-
tions for managing the common symptoms related to 
cancer treatments, leading to impaired food intake or 
malabsorption should be included, as well.  
When dietary measures fail to meet patients’ 
protein-calorie requirements as detected by nutri-
tional monitoring, the prescription of energy-dense 
ONS should be considered, due to their proven effi-
cacy in increasing protein-calorie intake (6, 21).  
Complementary therapies in the form of “natu-
ral” dietary supplements are frequently used and 
asked for by cancer patients. Their purported anti-
tumor effects are not yet demonstrated by appropriate 
efficacy evaluations, so their use cannot be recom-
mended. However, healthcare professionals involved 
in the nutritional treatment of cancer patients should 
be knowledgeable on this issue, in order to discuss 
with the patients the potential risks, benefits and ex-
pectations deriving from specific dietary supplement 
consumption (22).  
A healthy dietary pattern is known to be associ-
ated with reduced cancer risk (23), so it is reasonable 
to argue that it would reduce cancer recurrence, as 
well. However, the available clinical supporting evi-
dence is limited to reduction of fat intake in women 
with early-stage breast cancer (24). Since cancer and 
related treatments may be responsible for metabolic 
changes affecting nutritional requirements, dietary 
advice should be tailored to the individual patient 
and “hypocaloric alternative anti-cancer diets” (e.g. 
macrobiotic or vegan) are not recommended, as they 
could worsen protein-calorie intake with no proven 
benefits on recurrence rates (25).  
Finally, although recent animal model studies 
showed that pretreatment short-term starvation could 
improve chemotherapy (CT) efficacy and reduce tox-
icity by diminishing malignant cells’ resistance to 
drugs while protecting normal tissues (26), this hy-
pothesis still needs to be confirmed in humans. 
Therefore, this practice is not recommended, particu-
larly in malnourished patients and those at nutritional 
risk, since weight and lean body mass loss is associ-
ated with dose-limiting toxicity and mortality in pa-
tients undergoing CT (3, 10).  
Enteral Nutrition 
EN by means of tube feeding offers the possibil-
ity of increasing or ensuring nutrient intake whenever 
the gastrointestinal tract is functional and oral nutri-
tion is not feasible or remains inadequate despite nu-
tritional counseling and ONS consumption (6, 7, 27). 
EN should not be used routinely during anti-
cancer treatment in all patients, but only in those who 
are malnourished or judged to be unable to eat ade-
quately (the intention being to introduce an amount of 
calories ≥60% of estimated requirements) for more 
than 7 days (6, 7, 27). 
Tube feeding can either be delivered via 
trans-nasal (nasogastric / nasojejunal tube) or a per-
cutaneous route (percutaneous endoscopic / radio-
logically inserted / surgical gastrostomy or jejunos-
tomy). To date, there is insufficient evidence to rec-
ommend the best route in terms of efficacy and safety 
(27, 28); however, gastrostomy should be preferred for 
long term treatment (i.e. home artificial nutrition, 
HAN), as it may be more comfortable for patients and 
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easier to manage for care-givers, whereas trans-nasal 
tubes need to be replaced approximately every 6 
weeks (6, 7). Whenever trans-nasal tubes or gastros-
tomy placement is not feasible, as may be the case in 
severe obstructing esophageal or gastric cancer, nee-
dle catheter jejunostomy represents the most appro-
priate EN delivery route (6, 7, 27).  
With regards to timing, prophylactic feeding 
does not seem to offer advantages in terms of nutri-
tional outcomes, treatment interruptions and survival 
compared to reactive feeding, which is initiated once 
nutritional counseling and ONS have failed to satisfy 
energy requirements (27, 28). 
EN represents the first-line peri-operative nutri-
tional treatment also for surgical cancer patients re-
quiring artificial nutrition (6, 7). Both European and 
American guidelines recommend preoperative EN 
with immune-enhancing formulas, containing argi-
nine, ω-3 fatty acids and nucleotides, in cancer pa-
tients undergoing major head-neck or abdominal 
surgery (6, 7, 16), although the grade of this recom-
mendation is still being debated. Post-operative EN is 
recommended in surgical patients malnourished at 
the time of intervention, in those who cannot reinitiate 
oral nutrition early or when this is expected to be in-
adequate for more than 10 days (16).  
Parenteral Nutrition 
The use of PN in cancer patients has been de-
bated because of the risk of infection. Both European 
and American guidelines clearly stated that PN is 
indicated in patients receiving active cancer treatment 
who are malnourished or are facing a period longer 
than 7 days of inadequate energy intake when nutri-
tional counseling, ONS or EN are not feasible or inef-
fective (4, 7).  
Routine PN during cancer treatment is strongly 
not recommended (4, 7).  
A short period of PN (10-15 days) is indicated in 
patients with acute and severe mucositis, ileus or in-
tractable vomiting, whereas long-term PN (more than 
30 days) should be implemented in patients with in-
testinal failure due to extensive bowel resection, se-
vere malabsorption, mechanical bowel obstruction, in 
sub-acute or chronic radiation enteritis and in patients 
with graft versus host disease of the digestive tract (4, 
7). PN may also aid insufficient oral intake in hypo-
phagic patients with a working gut (supplemental 
PN) (27).  
PN is contraindicated in hemodynamically un-
stable patients, with ascites, severe organ failure, or in 
the presence of severe glycemic instability and it is 
rarely appropriate in incurable cancer patients with 
life expectancy shorter than 3 months, Karnowfsky 
score ≤ 50 or ECOG performance status ≥ 3 (4, 7, 15). 
For long-term PN, a tunneled-catheter or im-
planted chamber is needed. Peripherally inserted 
central catheters (PICC) can also be used.  
Rigorous monitoring, particularly of glycemia 
and electrolytes, should be implemented from the 
time of starting PN, in order to prevent clinical and 
metabolic complications and to evaluate the impact of 
PN on clinical outcomes.  
Home artificial nutrition and palliative 
care 
Home Artificial Nutrition (HAN) is a well estab-
lished extra-hospital therapy, which helps to decrease 
the costs of health care, mostly by reducing the num-
ber and length of hospitalizations (29). HAN can im-
prove the prognosis of patients in several acute and 
chronic diseases, including cancer, and allows pa-
tients to integrate into their families and into society, 
thus improving their quality of life (30). Due to its 
organizational complexity, potentially serious com-
plications and the necessity of periodic outcomes as-
sessment, HAN should be prescribed and regularly 
monitored using defined protocols shared between 
oncologists and clinical nutrition specialists. 
Nutritional support, including HAN, may be 
also integrated into palliative care programs, when it 
is expected to be beneficial to quality of life and if it is 
estimated that patients may die from malnutrition 
prior to dying from cancer progression (4, 27). 
While patients who are not in the terminal phase 
of cancer may benefit from nutritional support and 
other medical therapies for cancer cachexia (31), 
low-quality evidence (i.e. in the absence of random-
ized trials) suggests that the administration of EN or 
PN in the last weeks of life does not change the course 
of the disease, so it may not be indicated (32).  
According to international guidelines, artificial 
nutrition may not be appropriate in incurable cancer 
patients with life expectancy shorter than 3 months or 
Karnowfsky score ≤ 50 or ECOG performance status ≥ 
3 (4, 6, 7, 15). 
In conclusion, nutritional support, including 
HAN, may be integrated into palliative care pro-
grams, according to individual-based evaluations, 
quality of life implications, life expectancy and pa-
tients’ awareness.  
Discussion 
It should be emphasized that malnutrition is an 
important issue in cancer patients, which should be 
appropriately managed by structured collaboration 
between oncologists and clinical nutrition specialists.  
The AIOM and SINPE recommend validated 
nutritional screening upon diagnosis and at regular 
time points in all patients with cancer type, stage or 
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treatment potentially affecting nutritional status, to-
gether with prompt referral to clinical nutrition ser-
vices or medical personnel with documented skills in 
clinical nutrition for comprehensive nutritional as-
sessment and support prescription.  
Well-designed clinical trials are needed to im-
prove the evidence in favour of nutritional support in 
different care settings for cancer patients. In addition, 
nutritional parameters should be considered as rele-
vant outcomes or potential confounders in outcome 
assessment in clinical oncology research. A summary 
of the AIOM-SINPE practical recommendations is 
reported in Table 1. 
 
TABLE 1. Summary of the AIOM-SINPE practical recommenda-
tions for nutritional support in cancer patients 
- Nutritional screening should be performed using validated tools (NRS 2002, 
MUST, MST, MNA) upon diagnosis and systematically repeated at regular 
time points in patients with cancer type, stage or treatment potentially af-
fecting nutritional status.  
- Patients at nutritional risk should be promptly referred for comprehensive 
nutritional assessment and support to clinical nutrition services or medical 
personnel with documented skills in clinical nutrition, specifically for cancer 
patients. 
- Nutritional support should be actively managed and targeted for each 
patient according to nutritional conditions, clinical status, planned treatment 
and expected outcome. It should comprise nutritional counseling with the 
possible use of oral nutritional supplements and/or artificial nutrition (en-
teral nutrition, total or supplemental parenteral nutrition) according to 
spontaneous food intake, tolerance and effectiveness.  
- Nutritional support and dietary modifications should aim to assist the 
maintenance or recovery of nutritional status by increasing or preserving 
protein and calorie intake. “Alternative hypocaloric anti-cancer diets” (e.g. 
macrobiotic or vegan diets) are not recommended. 
- Nutritional support may be integrated into palliative care programs, ac-
cording to individual-based evaluations, quality of life implications, life 
expectancy and patients’ awareness.  
- Home artificial nutrition should be prescribed and regularly monitored 
using defined protocols shared between oncologists and clinical nutrition 
specialists.  
- Nutritional parameters should be considered as relevant outcomes or po-
tential confounders in outcome assessment in clinical oncology research.   
- Well-designed clinical trials are needed to improve the evidence in favour of 
nutritional support in different care settings for cancer patients. 
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